The study is designed to evaluate the response of potential biomarkers generated by the CytoRADx assay on blood samples from human subjects receiving two general forms of radiation treatment: a) total body irradiation and b) localized fractionated radiation treatment for selected anatomic sites.
Blood samples will be obtained from patients undergoing radiation treatment as part of their standard of care treatment for their underlying disorder/disease which will usually be cancer. The samples will be obtained both prior to and following their radiation treatment.
The samples will then be shipped for comparison of CytoRADx results on various lymphocyte subsets in those patients' blood samples.
Roughly 8-10 million patients complaining of chest pain come to an Emergency Department (ED) annually in the United States. Quickly determining if you are having a heart attack is critical for improving your chances of survival. Cardiac troponin is a protein that is used as a biomarker (biological marker) to indicate damage to the heart muscle. Cardiac troponin lab tests that are currently used in the United States do not have the ability to detect low levels of troponin. There are more sensitive troponin tests that are primarily used outside the US, that are able to detect lower levels of cardiac troponin within 90-180 minutes instead of 5 or 6 hours. This allows for the early identification of individuals at a higher risk for heart damage and these patients benefit from early diagnosis and treatment. Delaying the treatment of a heart attack increases the chance of dying or being permanently disabled. This study will collect blood samples from people coming to the Emergency Department complaining of chest pain in order to measure this troponin lab test's ability to accurately detect troponin levels.